SEC Comment Letter 0000000000-25-003728 to NOVARTIS AG (NVS)

NOVARTIS AG
Date: April 8, 2025 · CIK: 0001114448 · Accession: 0000000000-25-003728

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-15024

Date

April 8, 2025

Author

Finance

Form

UPLOAD

Company

NOVARTIS AG

Letter

Re: Novartis AG For 20-F for Fiscal Year Ended December 31, 2024 Filed January 31, 2025 File No. 001-15024 Dear Harry Kirsch:

April 8, 2025

Harry Kirsch Chief Financial Officer Novartis AG Postfach CH-4002 Basel Switzerland

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 8, 2025

Harry Kirsch
Chief Financial Officer
Novartis AG
Postfach CH-4002 Basel
Switzerland

 Re: Novartis AG
 For 20-F for Fiscal Year Ended December 31, 2024
 Filed January 31, 2025
 File No. 001-15024
Dear Harry Kirsch:

 We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
</TEXT>
</DOCUMENT>

SecProbe.io